Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Telix Pharmaceuticals ( (AU:TLX) ) has issued an announcement.
Telix Pharmaceuticals has applied to the ASX for quotation of a small number of additional ordinary fully paid shares, totaling 41,161 securities, issued on various dates in November and December 2025 following the exercise of options or conversion of other securities. The incremental listing reflects routine capital management activity and a modest expansion of the company’s quoted share base, with limited immediate impact on overall capital structure but signalling ongoing execution of equity-linked incentives or financing arrangements.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$28.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialisation of radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Listed on the ASX under the code TLX, the company targets global oncology and molecular imaging markets with its portfolio of targeted radiation products.
Average Trading Volume: 1,878,341
Technical Sentiment Signal: Sell
Current Market Cap: A$4.01B
For an in-depth examination of TLX stock, go to TipRanks’ Overview page.